NeoplasmsSUCRENCT02900287
Cancer Survival in Reunion Island , 1998-2008 (SUCRE)
An observational study of Neoplasms, run by Centre Hospitalier Universitaire de la Réunion at 1 site in Reunion.
Trial summary
Cancer survival is important to determine prognostic of patients and evaluate care and prevention health strategies. Sucre is the first study to describe cancer survival in Reunion Island. Sucre aims at evaluating five year cancer prognostic in Reunion Island by cancer site and gender. Read more about this study
- Who is it for?
- Ages 15 years and older
- Conditions the study is for
- Neoplasms
- How many people
- 18,000 participants
- Where
- 1 siteReunion
- Study dates
- 1 Jan 2019to 31 Dec 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Study population extracted from Reunion Island Cancer Registry
Who may be able to join
- Patients domiciled in Reunion Island at diagnosis
- Patients with at least 15 years of age at diagnosis
- Patients with cancer diagnosis between 01/01/1998 and 31/12/2008
Who cannot join
- Cutaneous malignant cancer expected melanoma
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Survie Des Personnes Atteintes de Cancer à la Réunion, 1998-2008 (SUCRE)
Cancer survival is important to determine prognostic of patients and evaluate care and prevention health strategies. Sucre is the first study to describe cancer survival in Reunion Island. Sucre aims at evaluating five year cancer prognostic in Reunion Island by cancer site and gender. Sucre is a retrospective cohort study of cancer diagnosed between 01/01/1998 and 31/12/2008.
Read the detailed description
Data are extracted from Reunion Island Cancer Registry.
- Conditions
- Neoplasms
- Keywords
- Survival, Cancer
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
5 years related survival rate by cancer site and gender
Measured: 5 years
Secondary outcomes (3)
1, 3, 5 and 10 years related survival rate by cancer site and gender
Measured: 1, 3, 5 and 10 years
1, 3, 5 and 10 years standardised survival rate by cancer site and gender
Measured: 1, 3, 5 and 10 years
1, 3, 5 and 10 years related survival rate by age at diagnosis
Measured: 1, 3, 5 and 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2016 (estimated)
- Study start1 Jan 2019
- Primary completion31 Dec 2019
- Study completion31 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 18,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de la Réunion
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02900287
- Sponsor's protocol ID
- 2014/CHU/05
- Acronym
- SUCRE
- Status last verified
- Jan 2024
- First submitted
- 9 Sep 2016
- Last updated
- 5 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Survie Des Personnes Atteintes de Cancer à la Réunion, 1998-2008 (SUCRE)
- ClinicalTrials.gov ID
- NCT02900287
- Acronym / sponsor ID
- SUCRE / 2014/CHU/05
- Conditions
- Neoplasms
- Keywords
- Survival, Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 18,000 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de la RéunionUniversity, hospital or other
- Study start
- 1 Jan 2019 (actual)
- Primary completion
- 31 Dec 2019 (actual)
- Study completion
- 31 Dec 2019 (actual)
- First posted
- 14 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cancer survival is important to determine prognostic of patients and evaluate care and prevention health strategies. Sucre is the first study to describe cancer survival in Reunion Island. Sucre aims at evaluating five year cancer prognostic in Reunion Island by cancer site and gender. Sucre is a retrospective cohort study of cancer diagnosed between 01/01/1998 and 31/12/2008.
Detailed description
Data are extracted from Reunion Island Cancer Registry.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Study population extracted from Reunion Island Cancer Registry
Key inclusion criteria (3 listed)
- Patients domiciled in Reunion Island at diagnosis
- Patients with at least 15 years of age at diagnosis
- Patients with cancer diagnosis between 01/01/1998 and 31/12/2008
Key exclusion criteria (1 listed)
- Cutaneous malignant cancer expected melanoma
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
5 years related survival rate by cancer site and gender
Time frame: 5 years
3 secondary outcomes
1, 3, 5 and 10 years related survival rate by cancer site and gender
Time frame: 1, 3, 5 and 10 years
1, 3, 5 and 10 years standardised survival rate by cancer site and gender
Time frame: 1, 3, 5 and 10 years
1, 3, 5 and 10 years related survival rate by age at diagnosis
Time frame: 1, 3, 5 and 10 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2024.
- Individual participant dataSharing planned: No
Related trials for Neoplasms
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neoplasms, run by Centre Hospitalier Universitaire de la Réunion at 1 site in Reunion.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Reunion. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
5 years related survival rate by cancer site and gender (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2024.